Authors: Jean-Sébastien Claveau, Francis K. Buadi & Shaji Kumar
Abstract
Major progress in the treatment of multiple myeloma has been made in the last several years. However, myeloma remains incurable and patients with high-risk cytogenetics or advanced stage disease have an even worsen survival. Only allogeneic transplantation may have curative potential in some patients. However, the high non-relapse mortality and incidence of chronic graft-versus-host disease have raised controversy regarding this procedure. In this review, we will address the role of upfront and delayed allogeneic transplant.
Key Summary Points |
Most patients with multiple myeloma will eventually relapse and die from their disease. |
Allogeneic hematopoietic cell transplant is currently the only potentially curative therapy, supporting the existence of a graft-versus-myeloma effect. |
Access to an algorithm regarding clinical utilization of allogeneic transplant would benefit clinicians and researchers. |
New strategies are necessary to make allogeneic hematopoietic cell transplantation safer while reducing non-relapse mortality and chronic graft-versus-host disease. |
In young patients with ultra-high-risk disease, upfront allogeneic transplantation could be a valuable option in the context of clinical trials. |